Liminatus Pharma Warrants EBIT

The latest EBIT for LIMNW is $-3.1B as of September 2024. That is below the sector sector average of $-6.4M. Investors often review this figure alongside Liminatus Pharma Warrants's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, LIMNW currently prints $-3.1B for EBIT, while the sector average sits near $-6.4M. That is roughly 48619.3% below the sector mean. Large gaps often invite a closer look at Liminatus Pharma Warrants's growth, margins, and balance sheet.

A EBIT figure of $-3.1B for LIMNW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-6.4M. Explore the charts below for those layers of context.

After noting LIMNW's EBIT ($-3.1B), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.